|
1
|
Lazcano-Ponce EC, Miquel JF, Muñoz N,
Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista
G and Nervi F: Epidemiology and molecular pathology of gallbladder
cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gourgiotis S, Kocher HM, Solaini L,
Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J
Surg. 196:252–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malik IA, Aziz Z, Zaidi SH and Sethuraman
G: Gemcitabine and Cisplatin is a highly effective combination
chemotherapy in patients with advanced cancer of the gallbladder.
Am J Clin Oncol. 26:174–177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chatni SS, Sainani RS, Mehta SA and
Mohandas KM: Infusion chemotherapy with cisplatinum and
fluorouracil in the treatment of locally-advanced and metastatic
gallbladder cancer. J Cancer Res Ther. 4:151–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reddy N and Czuczman MS: Enhancing
activity and overcoming chemoresistance in hematologic malignancies
with bortezomib: Preclinical mechanistic studies. Ann Oncol.
21:1756–1764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peiffert D, Seitz JF, Rougier P, François
E, Cvitkovic F, Mirabel X, Nasca S, Ducreux M, Hannoun-Levi JM,
Lusinchi A, et al: Preliminary results of a phase II study of
high-dose radiation therapy and neoadjuvant plus concomitant
5-fluorouracil with CDDP chemotherapy for patients with anal canal
cancer: A French cooperative study. Ann Oncol. 8:575–581. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doval DC, Sekhon JS, Gupta SK, Fuloria J,
Shukla VK, Gupta S and Awasthy BS: A phase II study of gemcitabine
and cisplatin in chemotherapy-naive, unresectable gall bladder
cancer. Br J Cancer. 90:1516–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bleiberg H, Conroy T, Paillot B, Lacave
AJ, Blijham G, Jacob JH, Bedenne L, Namer M, de Besi P, Gay F, et
al: Randomised phase II study of cisplatin and 5-fluorouracil
(5-FU) versus cisplatin alone in advanced squamous cell oesophageal
cancer. Eur J Cancer. 33:1216–1220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sohn BS, Yuh YJ, Kim KH, Jeon TJ, Kim NS
and Kim SR: Phase II trial of combination chemotherapy with
gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of
the bile duct, gallbladder, and ampulla of Vater. Tumori.
99:139–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roos WP and Kaina B: DNA damage-induced
cell death: From specific DNA lesions to the DNA damage response
and apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roos WP and Kaina B: DNA damage-induced
cell death by apoptosis. Trends Mol Med. 12:440–450. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jordan P and Carmo-Fonseca M: Molecular
mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci.
57:1229–1235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gosland M, Lum B, Schimmelpfennig J, Baker
J and Doukas M: Insights into mechanisms of cisplatin resistance
and potential for its clinical reversal. Pharmacotherapy. 16:16–39.
1996.PubMed/NCBI
|
|
15
|
Liu YX, Wang J, Guo J, Wu J, Lieberman HB
and Yin Y: DUSP1 is controlled by p53 during the cellular response
to oxidative stress. Mol Cancer Res. 6:624–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bang YJ, Kwon JH, Kang SH, Kim JW and Yang
YC: Increased MAPK activity and MKP-1 overexpression in human
gastric adenocarcinoma. Biochem Biophys Res Commun. 250:43–47.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang HY, Cheng Z and Malbon CC:
Overexpression of mitogen-activated protein kinase phosphatases
MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229–237. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vicent S, Garayoa M, López-Picazo JM,
Lozano MD, Toledo G, Thunnissen FB, Manzano RG and Montuenga LM:
Mitogen-activated protein kinase phosphatase-1 is overexpressed in
non-small cell lung cancer and is an independent predictor of
outcome in patients. Clin Cancer Res. 10:3639–3649. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Denkert C, Schmitt WD, Berger S, Reles A,
Pest S, Siegert A, Lichtenegger W, Dietel M and Hauptmann S:
Expression of mitogen-activated protein kinase phosphatase-1
(MKP-1) in primary human ovarian carcinoma. Int J Cancer.
102:507–513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C, Shi Y, Du Y, Ning X, Liu N, Huang
D, Liang J, Xue Y and Fan D: Dual-specificity phosphatase DUSP1
protects overactivation of hypoxia-inducible factor 1 through
inactivating ERK MAPK. Exp Cell Res. 309:410–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cortes-Sempere M, Chattopadhyay S, Rovira
A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P,
Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, et al: MKP1
repression is required for the chemosensitizing effects of
NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung
cancer. Cancer Lett. 286:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Small GW, Shi YY, Higgins LS and Orlowski
RZ: Mitogen-activated protein kinase phosphatase-1 is a mediator of
breast cancer chemoresistance. Cancer Res. 67:4459–4466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sánchez-Pérez I, Martínez-Gomariz M,
Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK
activation and apoptosis in response to cisplatin. Oncogene.
19:5142–5152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu
GS and Ravindranath Y: High level of mitogen-activated protein
kinase phosphatase-1 expression is associated with cisplatin
resistance in osteosarcoma. Pediatr Blood Cancer. 51:754–759. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Norton JN, Reynolds RP, Chan C, Valdivia
RH and Staats HF: Assessing the satisfaction and burden within an
academic animal care and use program. FASEB J. 31:3913–3921. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin SJ, Lee SO, Lee YF, Miyamoto H, Yang
DR, Li G and Chang C: TR4 nuclear receptor functions as a tumor
suppressor for prostate tumorigenesis via modulation of DNA
damage/repair system. Carcinogenesis. 35:1399–1406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai BL, Xu XF, Fu SM, Shen LL, Zhang J,
Guan SM and Wu JZ: Nuclear translocation of MRP1 contributes to
multidrug resistance of mucoepidermoid carcinoma. Oral Oncol.
47:1134–1140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stein U, Lage H, Jordan A, Walther W,
Bates SE, Litman T, Hohenberger P and Dietel M: Impact of BCRP/MXR,
MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of
atypical and classical multidrug resistant cancer cells. Int J
Cancer. 97:751–760. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ
and Xia Q: HIF1 regulates WSB-1 expression to promote
hypoxia-induced chemoresistance in hepatocellular carcinoma cells.
FEBS Lett. 587:2530–2535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu F, Gore AJ, Wilson JL and Korc M:
DUSP1 is a novel target for enhancing pancreatic cancer cell
sensitivity to gemcitabine. PLoS One. 9:e849822014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Redon C, Pilch D, Rogakou E, Sedelnikova
O, Newrock K and Bonner W: Histone H2A variants H2AX and H2AZ. Curr
Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Celeste A, Petersen S, Romanienko PJ,
Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B,
Coppola V, Meffre E, Difilippantonio MJ, et al: Genomic instability
in mice lacking histone H2AX. Science. 296:922–927. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Svetlova MP, Solovjeva LV and Tomilin NV:
Mechanism of elimination of phosphorylated histone H2AX from
chromatin after repair of DNA double-strand breaks. Mutat Res.
685:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Yin DP, Liu YX, Baer R and Yin Y:
Dual specificity phosphatase 1/CL100 is a direct transcriptional
target of E2F-1 in the apoptotic response to oxidative stress.
Cancer Res. 67:6737–6744. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Breitwieser W, Lyons S, Flenniken AM,
Ashton G, Bruder G, Willington M, Lacaud G, Kouskoff V and Jones N:
Feedback regulation of p38 activity via ATF2 is essential for
survival of embryonic liver cells. Genes Dev. 21:2069–2082. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hernández Losa J, Parada Cobo C, Guinea
Viniegra J, Sánchez-Arevalo Lobo VJ, Ramón y Cajal S and
Sánchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based
therapy. Oncogene. 22:3998–4006. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weir NM, Selvendiran K, Kutala VK, Tong L,
Vishwanath S, Rajaram M, Tridandapani S, Anant S and Kuppusamy P:
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant
human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer
Biol Ther. 6:178–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mansouri A, Ridgway LD, Korapati AL, Zhang
Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained
activation of JNK/p38 MAPK pathways in response to cisplatin leads
to Fas ligand induction and cell death in ovarian carcinoma cells.
J Biol Chem. 278:19245–19256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yuan ZQ, Feldman RI, Sussman GE, Coppola
D, Nicosia SV and Cheng JQ: AKT2 inhibition of cisplatin-induced
JNK/p38 and Bax activation by phosphorylation of ASK1: Implication
of AKT2 in chemoresistance. J Biol Chem. 278:23432–23440. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jamieson ER and Lippard SJ: Structure,
recognition, and processing of cisplatin-DNA adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gong JG, Costanzo A, Yang HQ, Melino G,
Kaelin WG Jr, Levrero M and Wang JY: The tyrosine kinase c-Abl
regulates p73 in apoptotic response to cisplatin-induced DNA
damage. Nature. 399:806–809. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Danilov AV, Neupane D, Nagaraja AS,
Feofanova EV, Humphries LA, DiRenzo J and Korc M:
DeltaNp63alpha-mediated induction of epidermal growth factor
receptor promotes pancreatic cancer cell growth and
chemoresistance. PLoS One. 6:e268152011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lapensee EW, Tuttle TR, Fox SR and
Ben-Jonathan N: Bisphenol A at low nanomolar doses confers
chemoresistance in estrogen receptor-alpha-positive and negative
breast cancer cells. Environ Health Perspect. 117:175–180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sève P and Dumontet C: Chemoresistance in
non-small cell lung cancer. Curr Med Chem Anticancer Agents.
5:73–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nakamura M, Nakashima H, Abe T, Ensako T,
Yoshida K and Hino K: Gemcitabine-based adjuvant chemotherapy for
patients with advanced gallbladder cancer. Anticancer Res.
34:3125–3129. 2014.PubMed/NCBI
|
